Oxford Nanopore Technologies has raised £109.5m through a combination of £29.3m in new capital and the sale of £80.2m in secondary shares. This brings the total primary investment in the firm, to date, to £480m.
Last year, Oxford Nanopore Technologies’ highlights ranged from scaling up to population-scale sequencing with PromethION, to accurate, rapid testing in cancer and infectious disease.
The company also opened its first production facility in July. The building is designed to look like the firm’s MinION portable device for DNA and RNA sequencing.
As his name suggests, Tholstrup has a Danish background, so it seemed appropriate we meet in Ole & Steen in Oxford’s Westgate Centre. As one of the county’s key strengths […]
Crossref is a membership association of scholarly publishers which makes it easier to find, cite and link to academic content. “The company doesn’t hold the content but has a unique […]